Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (71)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gianni, A. M.
Right arrow Articles by Bonadonna, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gianni, A. M.
Right arrow Articles by Bonadonna, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:645-653, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease

A. M. Gianni1,3, S. Siena1, M. Bregni1, F. Lombardi2, L. Gandola2, P. Valagussa1 and G. Bonadonna1

1Cristina Gandini Bone Marrow Transplantation Unit, Division of Medical Oncology Milan
2Division of Radiotherapy, Istituto Nazionale Tumori Milan
3Istituto dt Scienze Mediche, University of Milan (A.M.G.) Italy

Correspondence to: A. M. Gianni, M.D., Reparto TMO, Divisione di Oncologia Medica, Istituto Nazionale Tlimori, Via Venezian 1, 20133 Milano, Italy

Although effective in achieving durable remission in selected tumors incurable by conventional-dose chemotherapy, high-dose regimens requiring bone marrow transplantation remain too toxic for widespread use. With the aim to improve the therapeutic index of high-dose therapy, we have developed a novel program whereby several non-cross-resistant agents (including total body irradiation at myeloablative dose) were delivered sequentially rather than concurrently. The regimen has been tested in 25 patients with Hodgkin's disease refractory to primary chemotherapy (MOPP and ABVD) or relapsed within 12 months after first complete remission. The efficacy of the sequential regimen (72% complete response rate, 49% event-free survival and freedom from progression at four years, with a median observation of 3.5 years for patients remaining alive) compares favorably with the activity so far reported for the most effective high-dose regimens. Toxicity was low; no toxic deaths occurred and only three life-threatening adverse events were documented after autografting. The excellent tolerability of the final myeloablative course most likely reflects the speed and completeness of haematologic recovery that followed the use of peripheral blood progenitors as the sole or additional source of myeloid stem cells. The reduction of haematologic toxicity was further emphasized when rhG-CSF was employed to both shorten post-chemotherapy neutropenic intervals and to collect large amounts of peripheral blood stem cells. We expect that the use of growth factors will have a major impact on the therapeutic index of high-dose regimens. This, in turn, will confirm their safety as primary treatment in selected high-risk subsets.

Hodgkin's disease, high-dose chemo-radiotherapy, autologous bone marrow transplantation, haemopoietic growth factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices
J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Constans, A. Sureda, M. J. Terol, R. Arranz, M. D. Caballero, A. Iriondo, I. Jarque, E. Carreras, J. M. Moraleda, D. Carrera, et al.
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome
Ann. Onc., May 1, 2003; 14(5): 745 - 751.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Ferme, N. Mounier, M. Divine, P. Brice, A. Stamatoullas, O. Reman, L. Voillat, J. Jaubert, P. Lederlin, P. Colin, et al.
Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
J. Clin. Oncol., January 15, 2002; 20(2): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Cardinale, M. T. Sandri, A. Martinoni, A. Tricca LabTech, M. Civelli, G. Lamantia, S. Cinieri, G. Martinelli, C. M. Cipolla, and C. Fiorentini
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
J. Am. Coll. Cardiol., August 1, 2000; 36(2): 517 - 522.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Elias
Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer*
Chest, December 1, 1999; 116 (2009): 531S - 538S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Sweetenham, A. M. Carella, G. Taghipour, D. Cunningham, R. Marcus, A. D. Volpe, D. C. Linch, N. Schmitz, and A. H. Goldstone
High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., October 1, 1999; 17(10): 3101 - 3109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Elias, J. Ibrahim, A. T. Skarin, C. Wheeler, M. McCauley, L. Ayash, P. Richardson, L. Schnipper, K. H. Antman, and E. Frei III
Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome
J. Clin. Oncol., April 1, 1999; 17(4): 1175 - 1175.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.